Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
POINTREAU, Yoann
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers	Recruiting	3	102	Europe	Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy	UNICANCER, GORTEC, National Cancer Institute, France	Squamous Cell Carcinoma of Head and Neck	10/25	10/29
SALTORL, NCT03340896: Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT	Active, not recruiting	3	256	Europe	Docetaxel, Taxotere, Cisplatin, Cisplatine, Fluorouracil, 5 FU, radiotherapy, radiation therapy	Groupe Oncologie Radiotherapie Tete et Cou	Head and Neck Squamous Cell Carcinoma	10/28	11/28
FIBROTHERME, NCT05874492: Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Postoperative Radiotherapy for Breast Cancer	Recruiting	N/A	110	Europe	Thermal cure with a primary dermatological indication	Association Francaise pour la Recherche Thermale, Floralis	Fibrosis, Breast Cancer	10/25	04/26
Okita, Yoshihiro
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24